AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7661494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (400 mg every 24 hours for 5 days)
Number of subjects: 30
Study 7661494 — intervention group
Group type: COMPARATOR
Intervention: Pivamdinocillin (400 mg every 6 hours for 5 days)
Number of subjects: 30
Study 3090954 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical splenorenal shunt (SRS)
Number of subjects: 94
Study 3090954 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 94
Study 3090954 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization associated with splenectomy (EGDS)
Number of subjects: 94
Study 30544335 — intervention group
Group type: EXPERIMENTAL
Intervention: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via intratumoral convection enhanced delivery (CED) at 0.125 µg/mL
Number of subjects: 5
Study 30544335 — intervention group
Group type: EXPERIMENTAL
Intervention: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via intratumoral convection enhanced delivery (CED) at 0.25 µg/mL
Number of subjects: 5
Study 30544335 — intervention group
Group type: EXPERIMENTAL
Intervention: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via CED
Number of subjects: 5
Study 27435094 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus short message service (SMS) involving personalized and evolving text messages sent on days 7 to 14 and months 1, 2, 4 and 6 after the suicide attempt.
Number of subjects: 0
Study 27435094 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 27435094 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus SMS
Number of subjects: 0
Study 25022834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake at 9 months
Number of subjects: 295
Study 25022834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake at 18 months
Number of subjects: 295
Study 25022834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceeding Recommended Daily Upper Level for sodium intake at 18 months
Number of subjects: 295
Study 25022834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of sodium at both ages
Number of subjects: 295
Study 25022834 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional sources of sodium at 18 months
Number of subjects: 295
Study 25022834 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding status and solids introduction
Number of subjects: 295
Study 22737706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol patch (TP)
Number of subjects: 80
Study 22737706 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 80
Study 20440023 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Developmental Horse‐Riding Program (SDHRP) in addition to regular occupational therapy
Number of subjects: 60
Study 20440023 — intervention group
Group type: COMPARATOR
Intervention: Regular occupational therapy only
Number of subjects: 60
Study 18702964 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive LDL-C lowering with lovastatin 40 to 80 mg/day (target LDL-C of 60 to 85 mg/dl)
Number of subjects: 1314
Study 18702964 — intervention group
Group type: COMPARATOR
Intervention: Moderate LDL-C lowering with lovastatin 2.5 to 5 mg/day (target LDL-C of 130 to 140 mg/dl)
Number of subjects: 1314
Study 18574557 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib diphosphate 50 mg once daily from day 1 through 15 with ketoconazole 400 mg on day 8 (n=7)
Number of subjects: 14
Study 18574557 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib diphosphate 125 mg once daily after day 16 (n=13)
Number of subjects: 14
Study 18574557 — intervention group
Group type: COMPARATOR
Intervention: Control group (Motesanib diphosphate alone)
Number of subjects: 14
Study 15346999 — intervention group
Group type: EXPERIMENTAL
Intervention: Charité artificial disc
Number of subjects: 304
Study 15346999 — intervention group
Group type: COMPARATOR
Intervention: BAK fusion
Number of subjects: 304
Study 11534896 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study 11534896 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 9309995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (10 kcal/kg/d)
Number of subjects: 33
Study 9309995 — intervention group
Group type: COMPARATOR
Intervention: Regular hospital care (Control)
Number of subjects: 33
Study 7512483 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 301
Study 7512483 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 301
Study 3011876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (60 gm/day)
Number of subjects: 208
Study 3011876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal (60 gm/day)
Number of subjects: 208
Study 3011876 — intervention group
Group type: COMPARATOR
Intervention: No oat products (Control group)
Number of subjects: 208
Study 3011876 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (oat products)
Number of subjects: 208
Study 30478804 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session intervention involving HIV testing and counseling (n=199)
Number of subjects: 396
Study 30478804 — intervention group
Group type: COMPARATOR
Intervention: HIV testing and counseling only (n=197)
Number of subjects: 396
Study 30478804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 396
Study 29992591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 0
Study 27531571 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported priority symptoms (PS)
Number of subjects: 150
Study 27531571 — intervention group
Group type: COMPARATOR
Intervention: Clinician-documented symptoms
Number of subjects: 150
Study 27531571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for patient-reported priority symptoms (PS)
Number of subjects: 150
Study 27531571 — intervention group
Group type: COMPARATOR
Intervention: No intervention for patient-reported priority symptoms (PS)
Number of subjects: 150
Study 24700403 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine (0.2-8 μg·kg(‐1)·min(‐1))
Number of subjects: 100
Study 24700403 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) (0.4 μg·kg(‐1)·min(‐1) to a clinician‐determined maximum dose)
Number of subjects: 100
Study 24700403 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 100
Study 24700403 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 100
Study 23153395 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with five home visits (two before and three after birth) to provide maternal and neonatal care and linkages to facility care.
Number of subjects: 63
Study 23153395 — intervention group
Group type: COMPARATOR
Intervention: Standard care provided by the district in control areas.
Number of subjects: 63
Study 19230981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day, 20 mg/day, or 30 mg/day)
Number of subjects: 179
Study 19230981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 19230981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 179
Study 19230981 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole and Placebo
Number of subjects: 179
Study 17233683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subjects without dementia)
Number of subjects: 763
Study 15584487 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta treatment
Number of subjects: 0
Study 11425410 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase alone (standard-dose)
Number of subjects: 16588
Study 11425410 — intervention group
Group type: COMPARATOR
Intervention: Reteplase plus abciximab (half-dose reteplase and full-dose abciximab)
Number of subjects: 16588
Study 11425410 — intervention group
Group type: COMPARATOR
Intervention: Reteplase plus abciximab
Number of subjects: 16588
Study 11425410 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase alone
Number of subjects: 16588
Study 10178617 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivationally tailored intervention
Number of subjects: 1559
Study 10178617 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 1559
Study 8037103 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg torsemide
Number of subjects: 49
Study 8037103 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg torsemide
Number of subjects: 49
Study 8037103 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg torsemide
Number of subjects: 49
Study 8037103 — intervention group
Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 49
Study 3183341 — intervention group
Group type: EXPERIMENTAL
Intervention: 16,16‐dimethyl‐prostaglandin E2 1 micrograms/kg b.w. (pretreatment)
Number of subjects: 0
Study 3183341 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 0
Study 3183341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin alone (without alcohol)
Number of subjects: 0
Study 29411532 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sodium phytate dentifrice (0.85% w/w, RDA ∼130)
Number of subjects: 224
Study 29411532 — intervention group
Group type: COMPARATOR
Intervention: Reference dentifrice (RDA ∼43)
Number of subjects: 224
Study 28800328 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐Intensity Functional Exercise program
Number of subjects: 186
Study 28800328 — intervention group
Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 186
Study 26171933 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole
Number of subjects: 120
Study 26171933 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg fulvestrant
Number of subjects: 120
Study 23995175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Day Centre program (RDC)
Number of subjects: 50
Study 23995175 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list for RDC)
Number of subjects: 50
Study 20952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire insertion at +10° angle
Number of subjects: 5
Study 20952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire insertion at 0° angle
Number of subjects: 5
Study 20952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire insertion at -10° or -20° angles
Number of subjects: 5
Study 18356332 — intervention group
Group type: EXPERIMENTAL
Intervention: Macadamia nut-rich diet (42.5 g, 1.5 ounces, 33% total fat; 7% SFA, 18% MUFA, 5% PUFA)
Number of subjects: 25
Study 18356332 — intervention group
Group type: EXPERIMENTAL
Intervention: Macadamia nut-rich diet
Number of subjects: 25
Study 18356332 — intervention group
Group type: COMPARATOR
Intervention: Average American diet (AAD; 33% total fat; 13% SFA, 11% MUFA, 5% PUFA)
Number of subjects: 25
Study 16554388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (mental arithmetic test)
Number of subjects: 19
Study 12519049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone added to monthly triptoreline (3.75 mg every 28 days IM) treatment for six months.
Number of subjects: 20
Study 12519049 — intervention group
Group type: COMPARATOR
Intervention: Monthly triptoreline (3.75 mg every 28 days IM) treatment for six months.
Number of subjects: 20
Study 12519049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone added to triptoreline treatment.
Number of subjects: 20
Study 12519049 — intervention group
Group type: COMPARATOR
Intervention: Triptoreline treatment.
Number of subjects: 20
Study 10508227 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN)
Number of subjects: 20
Study 10508227 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study 7497668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg subcutaneous every 12 hours
Number of subjects: 453
Study 7497668 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 units subcutaneous every 8 hours
Number of subjects: 453
Study 2286510 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic suggestions recited in English (n = 31)
Number of subjects: 67
Study 2286510 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic suggestions recited in French (n = 19)
Number of subjects: 67
Study 2286510 — intervention group
Group type: COMPARATOR
Intervention: Continuous white noise (n = 18)
Number of subjects: 67
Study 19803002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 500 mg
Number of subjects: 23
Study 19803002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 1 g
Number of subjects: 23
Study 19803002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 500 mg or 1 g
Number of subjects: 23
Study 30614267 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (HSMP)
Number of subjects: 324
Study 30614267 — intervention group
Group type: COMPARATOR
Intervention: Financial Self‐Management Program (FSMP)
Number of subjects: 324
Study 30614267 — intervention group
Group type: COMPARATOR
Intervention: No Program Preference (NPP)
Number of subjects: 324
Study 28822576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pembrolizumab every 2 weeks (n=279)
Number of subjects: 834
Study 28822576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pembrolizumab every 3 weeks (n=277)
Number of subjects: 834
Study 28822576 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ipilimumab every 3 weeks (n=278)
Number of subjects: 834
Study 26031737 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system with telephone support by a geriatrician
Number of subjects: 96
Study 26031737 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 96
Study 24183564 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (Resolute Integrity, Medtronic)
Number of subjects: 1811
Study 24183564 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (Promus Element, Boston Scientific)
Number of subjects: 1811
Study 21236514 — intervention group
Group type: EXPERIMENTAL
Intervention: Online video education
Number of subjects: 80
Study 19805702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine vaccine (succinylnorcocaine linked to recombinant cholera toxin B-subunit protein)
Number of subjects: 115
Study 19805702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 17509789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 2
Study 17509789 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 2
Study 17509789 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone/metronidazole
Number of subjects: 2
Study 15389235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 159
Study 11177086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone followed by 10 days of oral trimethoprim-sulfamethoxazole (IM + PO group)
Number of subjects: 69
Study 11177086 — intervention group
Group type: COMPARATOR
Intervention: Oral trimethoprim-sulfamethoxazole alone (PO group)
Number of subjects: 69
Study 9353802 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg controlled release oxybutynin tablet
Number of subjects: 17
Study 9353802 — intervention group
Group type: COMPARATOR
Intervention: 5-mg conventional oxybutynin tablet
Number of subjects: 17
Study 8216445 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of mosapride citrate (5 mg, 10 mg, 20 mg, 40 mg)
Number of subjects: 20
Study 8216445 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral dose of mosapride citrate (20 mg t.i.d. for one day, 10 mg t.i.d. for 8 days)
Number of subjects: 20
Study 8216445 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of mosapride citrate (10 mg) with food effect
Number of subjects: 20
Study 2957416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (20 micrograms per spray, two sprays in each nasal cavity, four times daily for 3 weeks)
Number of subjects: 25
Study 2957416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray
Number of subjects: 25
Study 2957416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 25
Study 31313942 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg once-daily, with dose reductions to 30 mg and 15 mg QD)
Number of subjects: 0
Study 28341525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs)
Number of subjects: 9
Study 28341525 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 9
Study 25924490 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical locked plate combined with coracoclavicular ligament reconstruction
Number of subjects: 42
Study 25924490 — intervention group
Group type: COMPARATOR
Intervention: Clavicular hook plate
Number of subjects: 42
Study 25924490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 23603653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored safety information from a computer kiosk
Number of subjects: 720
Study 23603653 — intervention group
Group type: COMPARATOR
Intervention: Generic information from a computer kiosk
Number of subjects: 720
Study 21844547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir, 75 mg twice daily
Number of subjects: 410
Study 21844547 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxingshigan-yinqiaosan decoction, 200 mL 4 times daily
Number of subjects: 410
Study 21844547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir plus maxingshigan-yinqiaosan
Number of subjects: 410
Study 21844547 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 410
Study 21844547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir plus maxingshigan-yinqiaosan compared with oseltamivir
Number of subjects: 410
Study 21844547 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 410
Study 18998193 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirator retractor used during socket preparation and cementation
Number of subjects: 38
Study 18998193 — intervention group
Group type: COMPARATOR
Intervention: Standard cementing techniques without aspirator retractor
Number of subjects: 38
Study 16430545 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of isobaric bupivacaine
Number of subjects: 48
Study 16430545 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg of isobaric bupivacaine
Number of subjects: 48
Study 16430545 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of isobaric bupivacaine
Number of subjects: 48
Study 16430545 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg of isobaric bupivacaine
Number of subjects: 48
Study 16430545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of isobaric bupivacaine
Number of subjects: 48
Study 16430545 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of isobaric bupivacaine
Number of subjects: 48
Study 15616753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure hemorrhoidectomy
Number of subjects: 49
Study 15616753 — intervention group
Group type: COMPARATOR
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 49
Study 15616753 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 49
Study 10650733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rape-prevention program (the men's program)
Number of subjects: 145
Study 10650733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study 9282235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized L-NAME (15 mg in saline)
Number of subjects: 9
Study 9282235 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study 8356861 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg orally)
Number of subjects: 95
Study 8356861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg orally)
Number of subjects: 95
Study 8356861 — intervention group
Group type: COMPARATOR
Intervention: Control (no antacid therapy)
Number of subjects: 95
Study 3296121 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 47
Study 3296121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3041822 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl tablets administered once daily at bedtime
Number of subjects: 21
Study 3041822 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur tablets administered twice daily
Number of subjects: 21
Study 3041822 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl tablets
Number of subjects: 21
Study 31815977 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM‐C grafts (test group)
Number of subjects: 32
Study 31815977 — intervention group
Group type: COMPARATOR
Intervention: No graft (control group)
Number of subjects: 32
Study 30450781 — intervention group
Group type: EXPERIMENTAL
Intervention: PrOD + R (paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin) for 12 weeks
Number of subjects: 25
Study 26791440 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema therapy (ST) training with peer supervision and limited expert supervision after a 4-day training.
Number of subjects: 16
Study 26791440 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer supervision during ST training.
Number of subjects: 16
Study 26791440 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning in ST training.
Number of subjects: 16
Study 26791440 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic teaching in ST training.
Number of subjects: 16
Study 26262036 — intervention group
Group type: EXPERIMENTAL
Intervention: Text prediction functions for structured data entry
Number of subjects: 52
Study 26262036 — intervention group
Group type: EXPERIMENTAL
Intervention: Text prediction functions for unstructured data entry
Number of subjects: 52
Study 26262036 — intervention group
Group type: EXPERIMENTAL
Intervention: Text prediction functions
Number of subjects: 52
Study 22358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintering temperatures of 1,400°C to 1,550°C
Number of subjects: 198